Special Issue "Meningioma: Genomic Discoveries and Recent Therapeutic Advances "
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 15 November 2020.
Interests: neuro-oncology; glioblastoma; meningioma; oncolytic virus; herpes simplex virus; gene therapy
Special Issues and Collections in MDPI journals
Special Issue in Cancers: Glioblastoma: State of the Art and Future Perspectives
Translational Neuro-Oncology Laboratory, Department of Neurosurgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
Interests: central nervous system tumors; meningioma; glioma; genomics and personilized medicine; biomarkers; drug discovery
Meningioma are the most common primary intracranial tumor, representing up to 35% of all central nervous system neoplasms. Initial standard-of-care therapy for meningioma is surgical resection, followed by radiation in recurrent, atypical, or malignant meningioma. Nevertheless, the post-treatment clinical course of the disease is remarkably heterogeneous; while most low-grade meningiomas do not recur after resection, recurrence in atypical and anaplastic meningioma is frequent.
The evidence base for traditional chemotherapeutics is poor, and securing durable, long-term disease control in this setting has been challenging. Therefore, there is an unmet need to better identify patients who are at risk to develop progressive meningioma with an aggressive clinical course. Recent genomic and epigenmoic discoveries have provided us with an improved understanding of the molecular drivers in meningioma and novel approaches to their treatment, while also redefining the role of genomic screening for meningioma classification and prognostic stratification. On the other hand, the role of the tumor microenvironment and immune surveilance in meningioma biology is poorly understood.
This Special Issue therefore covers new original research articles and timely reviews from experts in the field of menigioma in basic, translational, and clinical research arenas. Emphasis will be on genomic discoveries and recent therapeutic advancements in meningioma. However, cutting-edge research in other areas, such as novel biomarkers, diagnostic modalities, the tumor microenvironment, and immunology, is also welcome.
Dr. Hiroaki Wakimoto
Dr. Tareq A. Juratli
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- molecular targets
- targeted therapy